MYUNGMOON Pharm Co., Ltd.

As of June 30, 2026, MYUNGMOON Pharm Co., Ltd. carries a market capitalization of 42.52B, placing it among publicly traded companies globally. Its enterprise value stands at 110.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, MYUNGMOON Pharm Co., Ltd. has 33.43M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.21, and the price-to-book ratio stands at 0.44.

As of June 30, 2026, MYUNGMOON Pharm Co., Ltd. trades at an EV/EBITDA multiple of 28.75 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 72.49 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 110.42B versus a market cap of 42.52B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, MYUNGMOON Pharm Co., Ltd. maintains a current ratio of 1.06, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 84.91, indicating elevated leverage, while an interest coverage ratio of 0.82 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, MYUNGMOON Pharm Co., Ltd. posted a negative return on equity (ROE) of -1.70, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -0.58, reflecting losses generated across the asset base. The company generates approximately 653.02M in revenue per employee across its workforce of 306.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.17 indicates how many times MYUNGMOON Pharm Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, MYUNGMOON Pharm Co., Ltd. recorded 203.78M in income tax expense. The company reported a pretax loss of -2.36B and -1.67B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, MYUNGMOON Pharm Co., Ltd.'s stock has declined approximately 26.37% over the past 52 weeks. The 50-day moving average sits at 1,251.56, while the 200-day moving average is 1,520.68.

Over the twelve months ended June 30, 2026, MYUNGMOON Pharm Co., Ltd. generated 199.82B in revenue and converted that into -1.67B in net income, yielding earnings per share of -76.37. EBITDA reached 3.84B, while operating income came in at 1.52B.

As of June 30, 2026, MYUNGMOON Pharm Co., Ltd. holds 24.31B in cash and equivalents against 87.15B in total debt, resulting in a net debt position of 62.06B. Total book value stands at 97.59B, with working capital of 7.01B providing operational flexibility.

MYUNGMOON Pharm Co., Ltd. produced -3.55B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -6.36B in capital expenditures, free cash flow totaled -9.91B - equivalent to -295.12 per share.

Over the twelve months ended June 30, 2026, MYUNGMOON Pharm Co., Ltd. posted a gross margin of 55.84, reflecting its pricing power and cost economics. The operating margin of 0.76 and net profit margin of -0.83 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -23.20: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -60.44, meaning MYUNGMOON Pharm Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

MYUNGMOON Pharm Co., Ltd.'s most recent stock split took place on May 14, 2020 with a 491:504 split ratio.

As of June 30, 2026, MYUNGMOON Pharm Co., Ltd. has an Altman Z-Score of 0.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.